| Literature DB >> 26191365 |
Alexei S Karpov1, Payman Amiri2, Cornelia Bellamacina2, Marie-Helene Bellance1, Werner Breitenstein1, Dylan Daniel2, Regis Denay1, Doriano Fabbro1, Cesar Fernandez1, Inga Galuba1, Stephanie Guerro-Lagasse1, Sascha Gutmann1, Linda Hinh2, Wolfgang Jahnke1, Julia Klopp1, Albert Lai2, Mika K Lindvall2, Sylvia Ma2, Henrik Möbitz1, Sabina Pecchi2, Gabriele Rummel1, Kevin Shoemaker2, Joerg Trappe1, Charles Voliva2, Sandra W Cowan-Jacob1, Andreas L Marzinzik1.
Abstract
The discovery of inhibitors targeting novel allosteric kinase sites is very challenging. Such compounds, however, once identified could offer exquisite levels of selectivity across the kinome. Herein we report our structure-based optimization strategy of a dibenzodiazepine hit 1, discovered in a fragment-based screen, yielding highly potent and selective inhibitors of PAK1 such as 2 and 3. Compound 2 was cocrystallized with PAK1 to confirm binding to an allosteric site and to reveal novel key interactions. Compound 3 modulated PAK1 at the cellular level and due to its selectivity enabled valuable research to interrogate biological functions of the PAK1 kinase.Entities:
Keywords: PAK1; allosteric inhibitor; dibenzodiazepine; p21 activated kinase; tool compound
Year: 2015 PMID: 26191365 PMCID: PMC4499825 DOI: 10.1021/acsmedchemlett.5b00102
Source DB: PubMed Journal: ACS Med Chem Lett ISSN: 1948-5875 Impact factor: 4.345